The verdict
Our read at a glance.
Whether elamipretide's mitochondria-targeting mechanism produces real clinical benefit in the specific diseases it is studied for, separate from broad longevity and energy claims.
- The signal
- Elamipretide has been tested in randomized trials for Barth syndrome, primary mitochondrial myopathy, and other conditions, with mixed results, including trials that did not meet their main goals. Its development has continued in selected rare-disease settings.
- The unknown
- Whether it provides clear benefit in any specific approved-quality indication, and whether any mitochondrial effect is relevant outside those rare diseases, which has not been shown.
- Our read
- A real, targeted mitochondrial drug with a mixed record, not a longevity supplement. Elamipretide is genuinely investigational for specific rare diseases, but its results have been inconsistent, and it should not be read as a proven energy or anti-aging therapy.
The explainer
Watch the 30:24 explainer.
9.9K views · Jun 2026
The mechanism
How it works.
Elamipretide is a small synthetic four-amino-acid peptide that carries a positive charge, which draws it into the inner membrane of mitochondria. There it binds cardiolipin, a lipid that helps organize the machinery of energy production, and the idea is that stabilizing cardiolipin keeps that machinery working better in cells whose mitochondria are damaged. This is the rationale for testing it in mitochondrial diseases, where trial results have been mixed, and it has not been shown to help healthy mitochondria.
Safety & regulatory boundary
The consequential part.
Elamipretide is investigational and not an approved product. Its trial record is mixed, with some studies not meeting their endpoints. It is studied in specific rare diseases, and its mitochondrial mechanism does not validate general longevity, energy, or anti-aging claims. Research-labeled or compounded elamipretide is not an approved product, and its development status does not support use outside trials.
What's next
What we're watching.
Regulatory decisions in rare mitochondrial diseases, additional trial results, and whether any indication reaches approval.
Context
Why this is discussed.
Elamipretide is a leading example of a drug designed to target mitochondria, which makes it interesting both for rare mitochondrial diseases and, by extension, to people interested in aging and energy.
The evidence base
21 cited references.
Regulatory & labels1
Stealth Biotherapeutics Inc. (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2024-05-30
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2026-06-30
ClinicalTrials.gov · PHASE1/PHASE2 · COMPLETED · 2022-03-03
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-11-26
ClinicalTrials.gov · PHASE3 · COMPLETED · 2022-04-29
ClinicalTrials.gov · AVAILABLE · registry record
ClinicalTrials.gov · PHASE2 · COMPLETED · 2019-03-27
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2017-07-05
Indexed literature (PubMed)12
Nashine S · Cells · 2021
Tung C et al. · Int J Mol Sci · 2025
Rowe LW et al. · Expert Opin Pharmacother · 2025
Thompson WR et al. · Genet Med · 2024
Karaa A et al. · Neurology · 2023
Shirley M · Drugs · 2026
Obi C et al. · Heart Fail Rev · 2022
Adam MP et al. · 1993
Sabbah HN · Heart Fail Rev · 2022
Bangeas A et al. · Int J Mol Sci · 2025
Karaa A et al. · Orphanet J Rare Dis · 2024
Keep reading